Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | MMP1 | P03956 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16015868 | 1.00 | DPP4 (0.41) | DPP4CA1CA2CA12MMP1 | |
| SCHEMBL9963462 | 0.82 | DPP4 (0.39) | DPP4CA1CA2ALDH1A1POLB | |
| SCHEMBL19507003 | 0.80 | CA12 (0.34) | DPP4CA1CA2CA12MMP1 | |
| SCHEMBL22080181 | 0.80 | CA12 (0.34) | DPP4CA1CA2CA12MMP1 | |
| SCHEMBL12212142 | 0.78 | ALDH1A1 (0.35) | CA1CA2CA12MMP1MMP2 | |
| SCHEMBL13691202 | 0.78 | MME (0.46) | DPP4LMNA | |
| SCHEMBL19845930 | 0.77 | MMP1 (0.36) | DPP4CA1CA2CA12MMP1 | |
| SCHEMBL20907635 | 0.77 | MLYCD (0.38) | CA1CA2CA12MMP1MMP2 | |
| SCHEMBL21149312 | 0.77 | MLYCD (0.38) | CA1CA2CA12MMP1MMP2 | |
| SCHEMBL12884385 | 0.77 | CA1 (0.41) | DPP4CA1CA2CA12MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655239-B2 | Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof | Shanghai Institute of Material Medica, Chinese Academy of Sciences (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20170355797-A1 | MOLECULARLY IMPRINTED COPOLYMER COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF NEW HAMPSHIRE (US) | 2017-12-14 | — | — | US | disclosed |
| US-8354403-B2 | Pyrrolidine derived beta 3 adrenergic receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | PFIZER INC. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | DPP4 1841/4885CA1 4877/4885CA2 4152/4885 |
| US-20110028447-A1 | INDAZOLE DERIVATIVES | CNR1, CNR2, GPR119 | DPP4 3705/4885CA1 2678/4885CA2 1778/4885 |
| US-11655239-B2 | Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof | DDR2, DDR1, DOCK2 | DPP4 1931/4885CA1 4883/4885CA2 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.